Literature DB >> 17388801

TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.

N J Mutch1, L Thomas, N R Moore, K M Lisiak, N A Booth.   

Abstract

PAI-1 and alpha(2)-antiplasmin (alpha(2)AP) are the principal direct inhibitors of fibrinolytic proteases. Thrombin activatable fibrinolysis inhibitor (TAFI), a plasma procarboxypeptidase activated by thrombin-thrombomodulin to form TAFIa, also regulates fibrinolysis by modulating fibrin. In this study, the relative contributions of PAI-1, alpha(2)AP and TAFIa to inhibition of lysis were assessed. In platelet-poor plasma clots, alpha(2)AP, TAFIa and PAI-1 all inhibited lysis, as shown by the addition of neutralizing antibodies to alpha(2)AP and PAI-1 +/- CPI, a potato carboxypeptidase inhibitor. alpha(2)AP played the largest role in regulating plasma clot lysis, but neutralization of inhibitors in combinations was more effective in shortening lysis times, with a maximal effect when all three inhibitors were neutralized. In platelet-rich clots, a larger contribution of PAI-1 was evident. Tissue plasminogen activator induced lysis of model thrombi, made from whole blood, was approximately doubled on incorporation of CPI, illustrating a substantial contribution of TAFIa to inhibition of thrombus lysis. Similar increases in thrombus lysis were observed on inclusion of neutralizing antibodies to PAI-1 and alpha(2)AP, with alpha(2)AP playing the dominant role. Maximal thrombus lysis occurred upon neutralization of all three inhibitors. These observations suggest that, despite the differences in concentrations and activities of inhibitors, and the different modes of action, the roles of the three are complementary in both plasma clot lysis and thrombus lysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388801     DOI: 10.1111/j.1538-7836.2007.02430.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  28 in total

Review 1.  Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

Authors:  Anna Tjärnlund-Wolf; Helen Brogren; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2012-08-09       Impact factor: 7.914

2.  Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Edward F Plow; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2011-07-01       Impact factor: 5.422

3.  Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.

Authors:  Yuko Suzuki; Hideto Sano; Liina Mochizuki; Naoki Honkura; Tetsumei Urano
Journal:  Blood Adv       Date:  2020-11-10

4.  PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.

Authors:  Khalid Bajou; Stephanie Herkenne; Victor L Thijssen; Salvino D'Amico; Ngoc-Quynh-Nhu Nguyen; Ann Bouché; Sébastien Tabruyn; Mohammed Srahna; Jean-Yves Carabin; Olivier Nivelles; Cécile Paques; Ivo Cornelissen; Michelle Lion; Agnès Noel; Ann Gils; Stefan Vinckier; Paul J Declerck; Arjan W Griffioen; Mieke Dewerchin; Joseph A Martial; Peter Carmeliet; Ingrid Struman
Journal:  Nat Med       Date:  2014-06-15       Impact factor: 53.440

5.  Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of α2-antiplasmin.

Authors:  Satish Singh; Aiilyan K Houng; Guy L Reed
Journal:  Blood       Date:  2019-08-08       Impact factor: 22.113

6.  The antifibrinolytic function of factor XIII is exclusively expressed through α₂-antiplasmin cross-linking.

Authors:  Steven R Fraser; Nuala A Booth; Nicola J Mutch
Journal:  Blood       Date:  2011-04-06       Impact factor: 22.113

7.  Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.

Authors:  Satish Singh; Aiilyan Houng; Guy L Reed
Journal:  Circulation       Date:  2016-12-27       Impact factor: 29.690

8.  Reversing the deleterious effects of α2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.

Authors:  Aiilyan K Houng; Dong Wang; Guy L Reed
Journal:  Exp Neurol       Date:  2014-02-18       Impact factor: 5.330

9.  The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro.

Authors:  N J Mutch; N R Moore; C Mattsson; H Jonasson; A R Green; N A Booth
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

10.  Assessment of coronary heart disease risk by combined analysis of coagulation factors.

Authors:  Nena Aleksic; Yao-Wei W Wang; Chul Ahn; Harinder S Juneja; Aaron R Folsom; Kenneth K Wu
Journal:  Atherosclerosis       Date:  2008-03-14       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.